Andrey Alexeyenko
Overview
Explore the profile of Andrey Alexeyenko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1828
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prabhakaran S, Hocking A, Irani Y, Hussey M, Alexeyenko A, Dobra K, et al.
APMIS
. 2025 Feb;
133(3):e70006.
PMID: 40017229
The 2021 WHO classification of thoracic tumours recommends grading pleural mesothelioma to aid prognostication. Robustness of grading and morphological characterisation is key to its clinical utility, though validation of this...
2.
Yu Y, Bogdan M, Noman M, Parpal S, Bartolini E, Van Moer K, et al.
Mol Oncol
. 2024 Mar;
18(8):1904-1922.
PMID: 38506049
An immunosuppressive tumor microenvironment promotes tumor growth and is one of the main factors limiting the response to cancer immunotherapy. We have previously reported that inhibition of vacuolar protein sorting...
3.
Brink M, Berglin E, Mohammad A, Lundquist A, Gjertsson I, Alexeyenko A, et al.
Arthritis Rheumatol
. 2022 Dec;
75(6):996-1006.
PMID: 36533851
Objective: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a chronic relapsing condition with unknown etiology. To gain insight into the molecular processes underlying the disease, we examined biomarkers in blood...
4.
Alexeyenko A, Brustugun O, Eide I, Gencheva R, Kosibaty Z, Lai Y, et al.
Transl Lung Cancer Res
. 2022 Nov;
11(10):2064-2078.
PMID: 36386450
Background: Targeted therapy with tyrosine kinases inhibitors (TKIs) against epidermal growth factor receptor (EGFR) is part of routine clinical practice for EGFR mutant advanced non-small cell lung cancer (NSCLC) patients....
5.
Petrov I, Alexeyenko A
J Mol Biol
. 2022 Jun;
434(11):167528.
PMID: 35662462
Experimental biologists are often left alone with the task to download, process, and analyze big datasets in order to perform correlation or other simpler analyses. To address these issues, we...
6.
Alekseenko Z, Dias J, Adler A, Kozhevnikova M, van Lunteren J, Nolbrant S, et al.
Nat Commun
. 2022 Jun;
13(1):3046.
PMID: 35650213
Stem cell therapies for Parkinson's disease (PD) have entered first-in-human clinical trials using a set of technically related methods to produce mesencephalic dopamine (mDA) neurons from human pluripotent stem cells...
7.
Petrov I, Alexeyenko A
Elife
. 2022 May;
11.
PMID: 35593700
Late advances in genome sequencing expanded the space of known cancer driver genes several-fold. However, most of this surge was based on computational analysis of somatic mutation frequencies and/or their...
8.
Dias J, Alekseenko Z, Jeggari A, Boareto M, Vollmer J, Kozhevnikova M, et al.
Sci Adv
. 2020 Sep;
6(38).
PMID: 32938678
How time is measured by neural stem cells during temporal neurogenesis has remained unresolved. By combining experiments and computational modeling, we define a Shh/Gli-driven three-node timer underlying the sequential generation...
9.
Brink M, Lundquist A, Alexeyenko A, Lejon K, Rantapaa-Dahlqvist S
Arthritis Res Ther
. 2019 Dec;
21(1):288.
PMID: 31842970
Background: Antibodies and upregulated cytokines and chemokines predate the onset of rheumatoid arthritis (RA) symptoms. We aimed to identify the pathways related to the early processes leading to RA development,...
10.
Prediction of response to anti-cancer drugs becomes robust via network integration of molecular data
Franco M, Jeggari A, Peuget S, Bottger F, Selivanova G, Alexeyenko A
Sci Rep
. 2019 Feb;
9(1):2379.
PMID: 30787419
Despite the widening range of high-throughput platforms and exponential growth of generated data volume, the validation of biomarkers discovered from large-scale data remains a challenging field. In order to tackle...